0000000000649260

AUTHOR

Reinhold Kreutz

0000-0002-4818-211x

showing 5 related works from this author

Physician attitudes to blood pressure control

2011

OBJECTIVES: The Supporting Hypertension Awareness and Research Europe-wide (SHARE) physician survey aimed to qualify the key challenges that physicians face when trying to get patients to blood pressure (BP) goal. METHODS: The SHARE survey was open to physicians involved in the treatment of patients with hypertension, was anonymous, and was designed to take 15 min to complete. The survey included 45 questions covering physicians' demographic information, views on the BP targets recommended by the European Society of Hypertension-European Society of Cardiology guidelines, opinions on acceptable levels of BP control, and perceptions about the challenges associated with getting patients to BP …

AdultMaleBlood pressure controlHealth Knowledge Attitudes Practicemedicine.medical_specialtyBiomedical ResearchAttitude of Health PersonnelPhysiologyElevated bpMEDLINEBlood PressureRisk AssessmentPhysiciansSurveys and QuestionnairesInternal MedicineHumansMedicinePractice Patterns Physicians'Antihypertensive Agentsbusiness.industryGuideline adherenceGuidelineAwarenessMiddle AgedHealth SurveysEuropeBlood pressureCardiovascular DiseasesPhysician surveyFamily medicineHypertensionFemaleGuideline AdherenceCardiology and Cardiovascular MedicinebusinessRisk assessmentJournal of Hypertension
researchProduct

2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension

2018

International audience; These practice guidelines on the management of arterial hypertension are a concise summary of the more extensive ones prepared by the Task Force jointly appointed by the European Society of Hypertension and the European Society of Cardiology. These guidelines have been prepared on the basis of the best available evidence on all issues deserving recommendations; their role must be educational and not prescriptive or coercive for the management of individual subjects who may differ widely in their personal, medical and cultural characteristics. The members of the Task Force have participated independently in the preparation of these guidelines, drawing on their academi…

Malemedicine.medical_specialtyblood pressure measurementAdvisory Committees030204 cardiovascular system & hematologycombination therapyPotential conflict03 medical and health sciences0302 clinical medicineDevice therapyInternal medicineLifestyle interventionsecondary hypertensionInternal MedicineHumansMedicinedevice therapyadherence030212 general & internal medicineSocieties MedicalComputingMilieux_MISCELLANEOUSlifestyle interventionshypertension-mediated organ damageTask forcebusiness.industryGeneral Medicinespecial conditionsdrug therapy3. Good healthEuropeHypertensionBlood pressureCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCardiology and Cardiovascular Medicinebusinessblood pressure treatment thresholds and targets
researchProduct

Nutraceuticals and blood pressure control: A European Society of Hypertension position document

2020

: High-normal blood pressure (BP) is associated with an increased risk of cardiovascular disease, however the cost-benefit ratio of the use of antihypertensive treatment in these patients is not yet clear. Some dietary components and natural products seems to be able to significantly lower BP without significant side effects. The aim of this position document is to highlight which of these products have the most clinically significant antihypertensive action and wheter they could be suggested to patients with high-normal BP. Among foods, beetroot juice has the most covincing evidence of antihypertensive effect. Antioxidant-rich beverages (teas, coffee) could be considered. Among nutrients, …

Blood pressure controlPhysiologyPhysiologyDisease030204 cardiovascular system & hematologyResveratrolBeetroot JuiceAntioxidantsMelatoninBeveragesdietary supplements03 medical and health scienceschemistry.chemical_compoundPrehypertensionblood pressure; consensus; dietary supplements; food; nutraceuticals0302 clinical medicineNutraceuticalInternal MedicinemedicineHumansMagnesium030212 general & internal medicineAntihypertensive AgentsMelatoninBlood pressure consensus dietary supplements food nutraceuticalsnutraceuticalsVitamin Cbusiness.industryfoodblood pressureBlood pressurechemistryconsensusHypertensionPotassiumCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement.

2021

High blood pressure (BP) is the leading modifiable risk factor for morbidity and mortality worldwide. The basis for diagnosing and managing hypertension is the measurement of BP, which is routinely used to initiate or rule out costly investigations and long-term therapeutic interventions. Inadequate measurement methodology or use of inaccurate BP measuring devices can lead to overdiagnosis and unnecessary treatment, or underdiagnosis and exposure to preventable cardiovascular disease (CVD). [...]

medicine.medical_specialtyPhysiologybusiness.industryMEDLINEBlood PressureBlood Pressure Determination030204 cardiovascular system & hematologyBlood Pressure Monitoring Ambulatory03 medical and health sciences0302 clinical medicineBlood pressureEmergency medicineAmbulatoryHypertensionInternal MedicinemedicineHumansBlood pressure monitoring030212 general & internal medicineHypertension diagnosisCardiology and Cardiovascular Medicinebusiness
researchProduct

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with…

2018

Summary Venous thromboembolism (VTE)‐BLEED, a decision tool for predicting major bleeding during chronic anticoagulation for VTE has not yet been validated in practice‐based conditions. We calculated the prognostic indices of VTE‐BLEED for major bleeding after day 30 and day 90, as well as for recurrent VTE and all‐cause mortality, in 4457 patients enrolled in the international, prospective XALIA study. The median at‐risk time was 190 days (interquartile range 106–360). The crude hazard ratio (HR) for major bleeding after day 30 was 2·6 [95% confidence interval (CI) 1·3–5·2] and the treatment‐adjusted HR was 2·3 (95% CI 1·1–4·5) for VTE‐BLEED high (versus low) risk patients: the correspondi…

AdultMalemedicine.medical_specialtyvenous thromboembolismHemorrhage030204 cardiovascular system & hematologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineInterquartile rangePredictive Value of TestsInternal medicinemedicineanticoagulation therapy; bleeding; prediction; rivaroxaban; venous thromboembolism; HematologyHumans030212 general & internal medicinecardiovascular diseasesProspective StudiesAdverse effectrivaroxabanRivaroxabananticoagulation therapybusiness.industryIncidence (epidemiology)Platelets Haemostasis and ThrombosisHazard ratioHematologypredictionBleedMiddle Agedequipment and suppliesbleedingConfidence intervalddc:Survival RateCohortFemalebusinessmedicine.drugResearch Paper
researchProduct